Antibody humanization by framework shuffling

被引:54
作者
Dall'Acqua, WF
Damschroder, MM
Zhang, JL
Woods, RM
Widjaja, L
Yu, J
Wu, H
机构
[1] Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA
[2] NIH, Clncl Immunotherapy Sect, Bethesda, MD 20892 USA
关键词
antibody; framework; humanization; germline; library;
D O I
10.1016/j.ymeth.2005.01.005
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We report here the humanization of a mouse monoclonal antibody (mAb B233) using a new technique which we call framework shuffling. rnAb B233 was raised against the human receptor tyrosine kinase EphA2 which is selectively up-regulated in many cancer cell lines and as such constitutes an attractive target for cancer therapy. The six CDRs of B233 were fused in-frame to pools of corresponding individual human frameworks. These human frameworks encompassed all known heavy and light (K) chain human germline genes. The resulting Fab combinatorial libraries were then screened for binding to the antigen. A two-step selection process, in which the light and heavy chains of the parental mAb were successively humanized, resulted in the identification of several humanized variants that retained binding to EphA2. More precisely, after conversion to human IgG1, the dissociation constants of three select fully humanized variants ranged from 3 to 48 nM. This brings the best framework-shuffled, humanized binder within 5-fold of the avidity of parental mAb B233. Importantly, these humanized IgGs also possessed biochemical activities similar to those of parental mAb B233 as judged by induction of EphA2 phosphorylation. Thus, without requiring any rational design or structural information, this new humanization approach allows to rapidly identify various human framework combinations able to support the structural feature(s) of the CDRs which are essential for binding and functional activity. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:43 / 60
页数:18
相关论文
共 45 条
[1]   3-DIMENSIONAL STRUCTURE OF AN ANTIGEN-ANTIBODY COMPLEX AT 2.8-A RESOLUTION [J].
AMIT, AG ;
MARIUZZA, RA ;
PHILLIPS, SEV ;
POLJAK, RJ .
SCIENCE, 1986, 233 (4765) :747-753
[2]  
Banfield MJ, 1997, PROTEINS, V29, P161, DOI 10.1002/(SICI)1097-0134(199710)29:2<161::AID-PROT4>3.0.CO
[3]  
2-G
[4]   RAPID HUMANIZATION OF THE FV OF MONOCLONAL-ANTIBODY B3 BY USING FRAMEWORK EXCHANGE OF THE RECOMBINANT IMMUNOTOXIN B3(FV)-PE38 [J].
BENHAR, I ;
PADLAN, EA ;
JUNG, SH ;
LEE, B ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (25) :12051-12055
[5]   A VERY STRONG ENHANCER IS LOCATED UPSTREAM OF AN IMMEDIATE EARLY GENE OF HUMAN CYTOMEGALO-VIRUS [J].
BOSHART, M ;
WEBER, F ;
JAHN, G ;
DORSCHHASLER, K ;
FLECKENSTEIN, B ;
SCHAFFNER, W .
CELL, 1985, 41 (02) :521-530
[6]   PRODUCTION OF FUNCTIONAL CHIMAERIC MOUSE HUMAN-ANTIBODY [J].
BOULIANNE, GL ;
HOZUMI, N ;
SHULMAN, MJ .
NATURE, 1984, 312 (5995) :643-646
[7]   The human immunoglobulin kappa locus on yeast artificial chromosomes (YACs) [J].
BrensingKuppers, J ;
Zocher, I ;
Thiebe, R ;
Zachau, HG .
GENE, 1997, 191 (02) :173-181
[8]  
Carles-Kinch K, 2002, CANCER RES, V62, P2840
[9]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[10]  
Coffman KT, 2003, CANCER RES, V63, P7907